Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 34


Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas.

Antonelli M, Buttarelli FR, Arcella A, Nobusawa S, Donofrio V, Oghaki H, Giangaspero F.

J Neurooncol. 2010 Sep;99(2):209-15. doi: 10.1007/s11060-010-0129-5. Epub 2010 Feb 21.


Mutant metabolic enzymes are at the origin of gliomas.

Yan H, Bigner DD, Velculescu V, Parsons DW.

Cancer Res. 2009 Dec 15;69(24):9157-9. doi: 10.1158/0008-5472.CAN-09-2650. Epub . Review.


Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.

Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, Su SM.

Nature. 2009 Dec 10;462(7274):739-44. doi: 10.1038/nature08617. Epub .


Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues.

Horbinski C, Kofler J, Kelly LM, Murdoch GH, Nikiforova MN.

J Neuropathol Exp Neurol. 2009 Dec;68(12):1319-25. doi: 10.1097/NEN.0b013e3181c391be.


Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A.

Acta Neuropathol. 2009 Oct;118(4):469-74. doi: 10.1007/s00401-009-0561-9. Epub 2009 Jun 25.


Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.

Korshunov A, Meyer J, Capper D, Christians A, Remke M, Witt H, Pfister S, von Deimling A, Hartmann C.

Acta Neuropathol. 2009 Sep;118(3):401-5. doi: 10.1007/s00401-009-0550-z. Epub 2009 Jun 19.


IDH1 and IDH2 mutations in gliomas.

De Carli E, Wang X, Puget S.

N Engl J Med. 2009 May 21;360(21):2248; author reply 2249. doi: 10.1056/NEJMc090593. No abstract available.


IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.

Ichimura K, Pearson DM, Kocialkowski S, B├Ącklund LM, Chan R, Jones DT, Collins VP.

Neuro Oncol. 2009 Aug;11(4):341-7. doi: 10.1215/15228517-2009-025. Epub 2009 May 12.


Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers.

Kang MR, Kim MS, Oh JE, Kim YR, Song SY, Seo SI, Lee JY, Yoo NJ, Lee SH.

Int J Cancer. 2009 Jul 15;125(2):353-5. doi: 10.1002/ijc.24379.


Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.

Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, Yu W, Li Z, Gong L, Peng Y, Ding J, Lei Q, Guan KL, Xiong Y.

Science. 2009 Apr 10;324(5924):261-5. doi: 10.1126/science.1170944.


IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.

Watanabe T, Nobusawa S, Kleihues P, Ohgaki H.

Am J Pathol. 2009 Apr;174(4):1149-53. doi: 10.2353/ajpath.2009.080958. Epub 2009 Feb 26.


IDH1 and IDH2 mutations in gliomas.

Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD.

N Engl J Med. 2009 Feb 19;360(8):765-73. doi: 10.1056/NEJMoa0808710.


IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.

Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, Frattini M, Molinari F, Knowles M, Cerrato A, Rodolfo M, Scarpa A, Felicioni L, Buttitta F, Malatesta S, Marchetti A, Bardelli A.

Hum Mutat. 2009 Jan;30(1):7-11. doi: 10.1002/humu.20937.


Analysis of the IDH1 codon 132 mutation in brain tumors.

Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A.

Acta Neuropathol. 2008 Dec;116(6):597-602. doi: 10.1007/s00401-008-0455-2. Epub 2008 Nov 5.


An integrated genomic analysis of human glioblastoma multiforme.

Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW.

Science. 2008 Sep 26;321(5897):1807-12. doi: 10.1126/science.1164382. Epub 2008 Sep 4.


Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort.

Pollack IF, Hamilton RL, James CD, Finkelstein SD, Burnham J, Yates AJ, Holmes EJ, Zhou T, Finlay JL; Children's Oncology Group.

J Neurosurg. 2006 Nov;105(5 Suppl):418-24.


The influence of central review on outcome associations in childhood malignant gliomas: results from the CCG-945 experience.

Pollack IF, Boyett JM, Yates AJ, Burger PC, Gilles FH, Davis RL, Finlay JL; Children's Cancer Group.

Neuro Oncol. 2003 Jul;5(3):197-207.


Expression of p53 and prognosis in children with malignant gliomas.

Pollack IF, Finkelstein SD, Woods J, Burnham J, Holmes EJ, Hamilton RL, Yates AJ, Boyett JM, Finlay JL, Sposto R; Children's Cancer Group.

N Engl J Med. 2002 Feb 7;346(6):420-7.


Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort.

Pollack IF, Finkelstein SD, Burnham J, Holmes EJ, Hamilton RL, Yates AJ, Finlay JL, Sposto R; Children's Cancer Group.

Cancer Res. 2001 Oct 15;61(20):7404-7.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk